Feature | Published:

Gene therapy finds its niche

Nature Biotechnology volume 29, pages 121128 (2011) | Download Citation

  • An Erratum to this article was published on 06 May 2011

This article has been updated

Gene therapy is finally poised to make a contribution to the treatment of debilitating, highly penetrant genetic diseases that have proved intractable to other regimens.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 12 April 2011

    In the version of the article originally published, Table 1 left off AAV as a section heading. A number of products listed under Adenovirus should have been listed under AAV. Neurologix product NLXP10 was incorrectly listed under the heading of retrovirus, and in phase 2 of development. It should be listed under the heading AAV, and the phase of development should have read phase 2 completed. The errors have been corrected in the HMTL and PDF versions of the article.

References

  1. 1.

    Nat. Genet. 2, 93–98 (1992).

  2. 2.

    & Science 175, 949–955 (1972).

  3. 3.

    Anonymous. Nat. Med. 6, 1 (2000).

  4. 4.

    et al. J. Clin. Invest. 118, 3132–3142 (2008).

  5. 5.

    et al. Nat. Immunol. 11, 457–460 (2010).

  6. 6.

    (Accessed 26 October 2010).

  7. 7.

    et al. Mol. Ther. 18, 1173–1182 (2010).

  8. 8.

    et al. N. Engl. J. Med. 360, 447–458 (2009).

  9. 9.

    et al. Science 272, 263–267 (1996).

  10. 10.

    et al. Mov. Disord. published online, doi: 10.1002/mds.23442 (18 November 2010).

  11. 11.

    et al. Hum. Gene Ther. 21, 1273–1285 (2010).

  12. 12.

    Nat. Genet. 2, 93–98 (1992).

  13. 13.

    Science 212, 24–25 (1981).

  14. 14.

    et al. Science 270, 475–480 (1995).

  15. 15.

    et al. Science 270, 470–475 (1995).

  16. 16.

    Nat. Biotechnol. 23, 519–521 (2005).

  17. 17.

    et al. Science 288, 669–672 (2000).

  18. 18.

    & Science 314, 1232–1235 (2006).

  19. 19.

    et al. Proc. Natl. Acad. Sci. USA 103, 17372–17377 (2006).

  20. 20.

    et al. Lancet 374, 1597–1605 (2009).

  21. 21.

    et al. Nature 467, 318–322 (2010).

  22. 22.

    et al. Nat. Biotechnol. 26, 549–551 (2008).

  23. 23.

    et al. Nat. Biotechnol. 26, 561–569 (2008).

Download references

Author information

Affiliations

  1. Cormac Sheridan is a freelance writer based in Dublin

    • Cormac Sheridan

Authors

  1. Search for Cormac Sheridan in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.1769

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing